Overview

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

Status:
RECRUITING
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in the treatment of chemotherapy-induced anemia (CIA) in patients with non-myeloid malignancies
Phase:
PHASE2
Details
Lead Sponsor:
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Treatments:
Population Groups